# Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology Omics

> **NCT07454941** · — · ENROLLING_BY_INVITATION · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 4000 (estimated)

## Conditions studied

- Urothelial Carcinoma (UC)
- HER2
- Diagnostic

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07454941
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-03-02
- **Primary completion:** 2028-06-03
- **Final completion:** 2030-06-03
- **Target enrollment:** 4000 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07454941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07454941, "Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology Omics". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07454941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*